CRISPR-based gene editing has the potential to revolutionize biotechnology, agriculture, and medicine, allowing scientists to develop solutions for the world’s most pressing problems. Gene editing is widely used in plant engineering to improve food cultivation, to enable the sustainable production of chemicals and materials in industrial microorganisms, and to find treatments for diseases.
CRISPR technology enables breakthrough innovations by accelerating biological discovery and product innovation. However, challenges still remain with respect to the accessibility, scalability, and biosecurity considerations.
The widely used CRISPR systems are subject to many licensing limitations that hinder broad adoption of CRISPR technologies. Inscripta® democratizes genome editing by making its MAD7™ nuclease free for non-commercial academic and industrial applications. Learn more about the MAD7 nuclease and Inscripta’s MAD7 licensing program.
Performing multiple CRISPR edits per experiment is desirable to accelerate experiments, but very difficult to execute. This all changes with the introduction of trackable barcodes and digital workflow in Inscripta’s Onyx® Digital Genome Engineering Platform to dramatically increase the editing throughput.
The accessibility of CRISPR gene editing requires ensuring that genome engineering is executed safely. Inscripta’s proactive biosecurity screening process aims to identify and prevent both deliberate and accidental biorisk.